Ovarian serous tumor
MONDO:0037255A benign, borderline, or malignant epithelial tumor of the ovary characterized by the presence of neoplastic epithelial cells that, in well differentiated tumors, resemble the epithelial cells of the fallopian tube and, in poorly differentiated tumors, show anaplastic features. Approximately thirty to fifty percent of the tumors are bilateral. Grossly, the better differentiated tumors consist of cystic masses, usually unilocular, containing a clear but sometimes viscous fluid. Papillary formations are often present. The more malignant tumors tend to be solid and invasive, with areas of necrosis and hemorrhage.
Also known as: ovarian serous neoplasm, ovarian serous tumor, serous neoplasm of ovary, serous neoplasm of the ovary, serous tumor of ovary, serous tumor of the ovary, serous tumour of ovary, serous tumour of the ovary
1636 clinical trials for this condition and its sub-types, 6 tagged with Ovarian serous tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Ovarian serous tumor
-
Malignant ovarian serous tumor 5 trials · 203 incl. sub-types
1 sub-type
- Ovarian serous adenocarcinoma 199 trials · 203 incl. sub-types Sub-types →
-
Borderline ovarian serous tumor 11 trials
Most studied deeper sub-types
-
New drug combo aims to outsmart Platinum-Resistant ovarian cancer
Disease control OngoingThis phase 2 trial tests whether adding an experimental drug called M6620 (berzosertib) to standard gemcitabine chemotherapy helps women with ovarian, fallopian tube, or primary peritoneal cancer that came back after platinum-based treatment. About 70 participants will receive ei…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo may outperform chemo for returning ovarian cancer
Disease control OngoingThis study tests whether olaparib (a targeted drug) alone or combined with cediranib (which blocks tumor blood vessels) works better than standard platinum chemo for women whose ovarian, fallopian tube, or peritoneal cancer has returned after initial treatment. About 579 particip…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC